• PDF / 169,153 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 86 Downloads / 161 Views

DOWNLOAD

REPORT

---

1 S

Osteonecrosis of the jaw: 4 case reports In a study involving patients with metastatic prostate cancer diagnosed with osteonecrosis of the jaw (ONJ) between January 2006 and August 2009, four male patients [ages not stated] were described, who developed ONJ during treatment with zoledronic acid for metastatic prostate cancer. The male patients, who had metastatic prostate cancer, started receiving IV infusion of zoledronic acid [Zometa; dosage not stated]. The patients concomitantly receiving unspecified androgen deprivation therapy. However, the patients developed ONJ. Of them, three patients underwent in-patient periodontal surgery (n=1), dental implant (n=1) or root cannel surgery (n=1). In one patient, exposure to bone was spontaneous. Bantis A, et al. Bisphosphonate-induced osteonecrosis of the jaw in patients with bone metastatic, hormone-sensitive prostate cancer. Risk factors and prevention strategies. 803502364 Tumori 97: 479-483, No. 4, Aug 2011. Available from: URL: http://doi.org/10.1177/030089161109700411

0114-9954/20/1823-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 26 Sep 2020 No. 1823